The expanding spectrum of deep intronic mutations in the DMD gene underscores the necessity of integrating advanced genomic and transcriptomic approaches to resolve the molecular complexity of dystrophinopathies. The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.